Medications That Help with Breast Cancer And Bone Loss Prevention Part 2: Dr. Steven R. Goldstein1/26/2020 Dr. Steven R. Goldstein MD is an expert Obgyn in Manhattan, considered one of the nation’s top doctors in gynecology. In private practice for over 25 years, Dr. Goldstein has had patients who were excellent candidates for Evista (raloxifene) because of its dual effect of reducing breast cancer risk and preventing and treating osteoporosis. Another type of drugs, Aromotase inhibitors, also reduce the risk of breast cancer. These aromatase inhibitors are pure anti-estrogens (unlike the first two drugs, which are selective for the breast but not in all aspects of the body) these drugs contribute to osteoporosis, joint pain, vaginal atrophy, etc. Thus, in my opinion, while the aromatase inhibitors are excellent drugs for women with advanced breast cancers and can be lifesaving in such cases, their use for prevention of breast cancer, in women who don’t already have that disease, is inappropriate and unnecessary, especially in light of the high treatability when breast cancers are detected early. Furthermore, bone health, is as, if not more, important of an issue for long term healthy aging and quality of life as breast health. Since early detection of breast cancer will almost always result in a favorable outcome, and since women are routinely living much longer lives than previous generations, a fracture, especially of the hip, of a woman can be a much more life threatening and devastating event than an early breast cancer. Thus, drugs to prevent breast cancer that actually cause bone loss, like the aromatase inhibitors, in my opinion, make no sense for this purpose. To find out more about Dr. Steven R. Goldstein MD, an expert Obgyn in Manhattan, or schedule an appointment to discuss your gynecological conditions, visit www.goldsteinmd.com.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
December 2020
Categories |